Author(s)
Ma J1, Shi Y2, Zhu J3, Jiang W4, Li J5, Shen Z6, Cao G7, Zhang J7, Yang F8, Xuan J9
1Harbin Institute of Hematology and Oncology, Harbin, China, 2Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Lymphoma division，Beijing Cancer Hospital, Beijing, China, 4Cancer prevention and treatment center of Zhongshan University, guangzhou, China, 5Jiangsu Province Hospital, nanjing, China, 6Ruijin Hospital，Shanghai Jiaotong University School of Medicine, shanghai, China, 7Shenzhen Chipscreen Bioscience Ltd, shenzhen, China, 8Shanghai Centennial Scientific Ltd, Shanghai, China, 9Institute of Pharmaceutical Economics, Sun Yat - sen University, guangzhou, China
OBJECTIVES: Chidamide, a new subtype-selective HDACi, has been approved by CFDA as a new drugs for PTCL. This study was to assess the cost-effectiveness of Chidamide vs. chemotherapy in Chinese PTCL patients from a payer’s perspective. And to estimate the budgetary impact on health insurance fund after Chidamide adopted to national reimbursement drug list (NRDL). METHODS: A cost-effectiveness model and a budget impact model was constructed to assess the cost-effectiveness of Chidamide and chemotherapy in the treatment of PTCL and to estimate the potential budget impact once Chidamide is included in the national reimbursement drug list (NRDL) . Utility value and clinical data were obtained from published literature and from the Ⅱ phase clinical trial of chidamide. Cost data were collected from Chinese leading hospitals (Ruijin hospital, Beijing cancer hospital, Jiangsu Province Hospital etc.). The model calculated incremental cost effectiveness ratio (ICER) and increased health insurance fund in budget impact model. In the model, 4 scenarios were established to compare the two treatment regime (the 4 scenarios were defined with various combinations of market shares and pricing). A one-way sensitivity analysis was conducted for all parameters. RESULTS: Compared with chemotherapy, the ICER value for Chidamide was 107,419 Chinese Yuan (CNY)/QALY, which is lower than WHO recommended 3*GDP threshold (148,053 CNY/QALY, with 2015 Chinese GDP 49,351 CNY). The one-way sensitivity analysis demonstrated that the model result was not significantly impacted with all parameters increase or decrease 10% on the basis value, indicating the robustness of the model. After Chidamide adopted to NRDL, the budget impact model showed the health insurance fund would increase 111,271,753.9、、、 CONCLUSIONS: Chidamide is a cost effective treatment of PTCL in China compared to chemotherapy and will result very moderate increase on the insurance fund.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRM50
Topic
Economic Evaluation, Methodological & Statistical Research
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Modeling and simulation
Disease
Systemic Disorders/Conditions
